Cargando…
P087 A validation study of the limited channel single and multi-use NightOwl sleep testing systems compared to laboratory polysomnography in the diagnosis of obstructive sleep apnoea
BACKGROUND: Obstructive sleep apnoea (OSA) is common, and its prevalence is increasing. Opportunities to screen for OSA using simplified diagnostic devices may be important to addressing this clinical burden. The NightOwl (Ectosense NV, Leuven, Belgium) is a small dual channel device that acquires d...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10109160/ http://dx.doi.org/10.1093/sleepadvances/zpab014.131 |
Sumario: | BACKGROUND: Obstructive sleep apnoea (OSA) is common, and its prevalence is increasing. Opportunities to screen for OSA using simplified diagnostic devices may be important to addressing this clinical burden. The NightOwl (Ectosense NV, Leuven, Belgium) is a small dual channel device that acquires data from a single fingertip and is available in a disposable version, in addition to the previously validated reusable option. The devices will provide a measure of sleep duration and derived apnoea-hypopnoea index (AHI) using a proprietary algorithm. METHODS: A prospective cohort study of patients undergoing laboratory polysomnography (PSG) for suspected OSA is underway at Monash Medical Centre, Clayton (ACTRN12621000444886). Participants are fitted with a NightOwl Sensor Mini (disposable) and a NightOwl Sensor Reusable on their index and middle fingers, in addition to the standard PSG setup (Compumedics Grael, Profusion 3). The primary outcome is the level of agreement between the NightOwl Sensor Mini, NightOwl Sensor Reusable and PSG derived AHI. We also intend to compare the proprietary algorithm against Compumedics Profusion 3 for determination of oxygen desaturation index. Level of agreement will be determined utilising Bland-Altman plots. Progress to date Recruitment is currently underway with 29 of an intended 100 participants having completed their sleep studies. Intended outcome and impact The intended outcome of this study is to externally validate the two NightOwl devices against PSG for detecting OSA and accurately assessing severity. We anticipate this will enable screening for OSA in an efficient and cost-effective manner. |
---|